New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses – adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsack...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Lundstrom K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	immunotherapy viral vectors clinical trials drug approval Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/521c536d77ef43ef940735d343d5d01b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:521c536d77ef43ef940735d343d5d01b
record_format	dspace
spelling	oai:doaj.org-article:521c536d77ef43ef940735d343d5d01b2021-12-02T00:53:26ZNew frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy1177-5491https://doaj.org/article/521c536d77ef43ef940735d343d5d01b2018-02-01T00:00:00Zhttps://www.dovepress.com/new-frontiers-in-oncolytic-viruses-optimizing-and-selecting-for-virus--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses – adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses – have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Moreover, clinical trials have confirmed good safety profiles and therapeutic efficacy for oncolytic viruses. Most encouragingly, the first cancer gene-therapy drug – Gendicine, based on oncolytic adenovirus type 5 – was approved in China. Likewise, a second-generation oncolytic herpes simplex virus-based drug for the treatment of melanoma has been registered in the US and Europe as talimogene laherparepvec. Keywords: immunotherapy, viral vectors, clinical trials, drug approvalLundstrom KDove Medical Pressarticleimmunotherapyviral vectorsclinical trialsdrug approvalMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 43-60 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy viral vectors clinical trials drug approval Medicine (General) R5-920
spellingShingle	immunotherapy viral vectors clinical trials drug approval Medicine (General) R5-920 Lundstrom K New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
description	Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses – adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses – have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Moreover, clinical trials have confirmed good safety profiles and therapeutic efficacy for oncolytic viruses. Most encouragingly, the first cancer gene-therapy drug – Gendicine, based on oncolytic adenovirus type 5 – was approved in China. Likewise, a second-generation oncolytic herpes simplex virus-based drug for the treatment of melanoma has been registered in the US and Europe as talimogene laherparepvec. Keywords: immunotherapy, viral vectors, clinical trials, drug approval
format	article
author	Lundstrom K
author_facet	Lundstrom K
author_sort	Lundstrom K
title	New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
title_short	New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
title_full	New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
title_fullStr	New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
title_full_unstemmed	New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
title_sort	new frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/521c536d77ef43ef940735d343d5d01b
work_keys_str_mv	AT lundstromk newfrontiersinoncolyticvirusesoptimizingandselectingforvirusstrainswithimprovedefficacy
_version_	1718403438259208192

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

Ejemplares similares